Fig. 2: EFS, DFS and OS. | Nature Medicine

Fig. 2: EFS, DFS and OS.

From: Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial

Fig. 2

a, EFS in the ITT population. b, EFS subgroup analysis (n, number of individual patients in each subgroup; dashed line, HR in the ITT population; one patient with stage IV disease not included in subgroup analyses by stage). c, DFS in the ITT population. d, OS in the ITT population. IC, immune cells.

Back to article page